CU20100084A7 - USE OF A GESTAGEN IN COMBINATION WITH A STRATEGEN AND ONE OR VARIOUS EXCIPIENTS / PHARMACEUTICALLY ACCEPTABLE CARRIERS FOR ORACT-FREE ANTI-CONCEPTION WITHOUT LACTOSE - Google Patents
USE OF A GESTAGEN IN COMBINATION WITH A STRATEGEN AND ONE OR VARIOUS EXCIPIENTS / PHARMACEUTICALLY ACCEPTABLE CARRIERS FOR ORACT-FREE ANTI-CONCEPTION WITHOUT LACTOSEInfo
- Publication number
- CU20100084A7 CU20100084A7 CU20100084A CU20100084A CU20100084A7 CU 20100084 A7 CU20100084 A7 CU 20100084A7 CU 20100084 A CU20100084 A CU 20100084A CU 20100084 A CU20100084 A CU 20100084A CU 20100084 A7 CU20100084 A7 CU 20100084A7
- Authority
- CU
- Cuba
- Prior art keywords
- lactose
- pharmaceutically acceptable
- combination
- oract
- strategen
- Prior art date
Links
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 title abstract 2
- 239000003937 drug carrier Substances 0.000 title abstract 2
- 239000008101 lactose Substances 0.000 title abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 title abstract 2
- 239000000583 progesterone congener Substances 0.000 title abstract 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 2
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 abstract 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 abstract 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 abstract 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 abstract 1
- 229960001616 chlormadinone acetate Drugs 0.000 abstract 1
- 229960003309 dienogest Drugs 0.000 abstract 1
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 abstract 1
- 229960005309 estradiol Drugs 0.000 abstract 1
- 229960004766 estradiol valerate Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 229960002568 ethinylestradiol Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Los gestágenos, con preferencia dienogest, acetato de clormadinona o levornogetrel en combinación con estrógenos tales como, por ejemplo, etinilestradiol, 17beta-estradiol o valerato de estradiol y uno o varios excipientes/portadores farmacéuticamente aceptables realizan una anticoncepción oral sin lactosa. Se da una posibilidad para mejorar la prevención de la intolerancia a la glucosa en un factor que eventualmente contribuye con la mejoría, incluso en cuanto a costosos ensayos de la intolerancia a la glucosa. La intervención también es apropiada para un uso prolongado.The gestagens, preferably dienogest, chlormadinone acetate or levornogetrel in combination with estrogens such as, for example, ethinyl estradiol, 17 beta-estradiol or estradiol valerate and one or more pharmaceutically acceptable excipients / carriers perform oral contraception without lactose. There is a possibility to improve the prevention of glucose intolerance in a factor that eventually contributes to the improvement, even in terms of costly tests of glucose intolerance. The intervention is also appropriate for prolonged use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20100084A CU20100084A7 (en) | 2010-05-05 | 2010-05-05 | USE OF A GESTAGEN IN COMBINATION WITH A STRATEGEN AND ONE OR VARIOUS EXCIPIENTS / PHARMACEUTICALLY ACCEPTABLE CARRIERS FOR ORACT-FREE ANTI-CONCEPTION WITHOUT LACTOSE |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20100084A CU20100084A7 (en) | 2010-05-05 | 2010-05-05 | USE OF A GESTAGEN IN COMBINATION WITH A STRATEGEN AND ONE OR VARIOUS EXCIPIENTS / PHARMACEUTICALLY ACCEPTABLE CARRIERS FOR ORACT-FREE ANTI-CONCEPTION WITHOUT LACTOSE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20100084A7 true CU20100084A7 (en) | 2011-10-05 |
Family
ID=45000080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20100084A CU20100084A7 (en) | 2010-05-05 | 2010-05-05 | USE OF A GESTAGEN IN COMBINATION WITH A STRATEGEN AND ONE OR VARIOUS EXCIPIENTS / PHARMACEUTICALLY ACCEPTABLE CARRIERS FOR ORACT-FREE ANTI-CONCEPTION WITHOUT LACTOSE |
Country Status (1)
| Country | Link |
|---|---|
| CU (1) | CU20100084A7 (en) |
-
2010
- 2010-05-05 CU CU20100084A patent/CU20100084A7/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schindler | The “newer” progestogens and postmenopausal hormone therapy (HRT) | |
| AR082998A1 (en) | PHARMACEUTICAL ASSOCIATION TO TREAT AND / OR PREVENT MIOMA AND / OR ENDOMETRIOSIS, USE OF RESVERATROL AND PROGESTOGEN, PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF MIOMA AND / OR ENDOMETRIOSIS, MEDICATION FOR TREATMENT AND / OR PREPARATION OF MYOMA AND METHOD FOR TREATMENT AND / OR PREVENTION OF MIOMA AND / OR ENDOMETRIOSIS | |
| BR112014031910A2 (en) | Natural formulations and combination therapies for hormone replacement | |
| PE20080273A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING A PROGESTAGEN, A ESTROGEN AND A TETRAHYDROPHOLIC ACID | |
| MX363536B (en) | Nestorone®/estradiol transdermal gel. | |
| CL2011003172A1 (en) | Pharmaceutical composition comprising a) an exception, b) at least one sex steroid precursor, c) at least one selective estrogen receptor modulator or an antiestrogen and does not contain a progestin and / or an estrogen; pharmaceutical kit; and use to reduce or eliminate hot flashes, vasomotor symptoms, and night sweats. | |
| PE20120860A1 (en) | PHARMACEUTICAL COMBINATION INCLUDING LEVONORGESTREL IN COMBINATION WITH PYROXICAM, INDOMETACIN OR DICLOFENACO | |
| UA113549C2 (en) | BIOSABLED MEDICINAL DELIVERY MEASURES FOR HYDROPHOBIC COMPOSITIONS | |
| UY39175A (en) | CONTRACEPTIVE COMPOSITIONS WITH REDUCED ADVERSE EFFECTS | |
| JP2013018787A5 (en) | ||
| JP2010508275A5 (en) | ||
| ATE493132T1 (en) | MEDICINAL PRODUCTS COMPRISING AT LEAST ONE PROGESGEN | |
| EA200900491A1 (en) | USE OF ESTRADIOL VALERAT OR 17B-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL TREATMENT TO MAINTAIN AND / OR INCREASE SEXUAL TREATMENT IN THE SPECIAL WOMAN | |
| NI201000183A (en) | ANTIPROGESTIN DOSAGE REGIMES. | |
| PE20061415A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING GESTAGENS AND / OR ESTROGENS AND 5-METHYL- (6S) -TETRAHYDROFOLATE | |
| BRPI0512993A (en) | use of a pr antagonist, pharmaceutically useful kit, and method of contraception in a female of childbirth | |
| PE20070327A1 (en) | COMPOSITION INCLUDING A PROGESTIN AND A ESTROGEN | |
| UY30461A1 (en) | PHARMACEUTICAL COMPOSITION FOR ANTI-CONCEPTION AND TO REDUCE THE RISK OF CONGENITAL MALFORMATIONS. | |
| AR095691A1 (en) | FORMULATION OF AMORFO L-5-METHYLETHYDROPHOLATE (L-5-MTHF-Ca), PROCEDURE, USE | |
| JP2008515909A5 (en) | ||
| CU20100084A7 (en) | USE OF A GESTAGEN IN COMBINATION WITH A STRATEGEN AND ONE OR VARIOUS EXCIPIENTS / PHARMACEUTICALLY ACCEPTABLE CARRIERS FOR ORACT-FREE ANTI-CONCEPTION WITHOUT LACTOSE | |
| AR069195A1 (en) | USE OF A GESTAGEN IN COMBINATION WITH A STROGEN AND ONE OR VARIOUS EXCIPIENTS / PHARMACEUTICALLY ACCEPTABLE CARRIERS FOR ORACT WITHOUT LACTOSE ANTI-CONCEPTION | |
| EA200900829A1 (en) | PHARMACEUTICAL PREPARATION FOR REDUCING ENDOMETRIOSIS | |
| AR070302A1 (en) | PHARMACEUTICAL COMPOSITION OF A STEROID VAGINAL LIBERATION SYSTEM | |
| CR11211A (en) | ESTRATIENS 8-BETA-SUBSTITUTED AS SELECTIVE ACTION STROGENS |